The experimental biotech startup Verve Therapeutics has paused the first phase of a human gene-editing trial due to strange side effects in a patient. The trial aims to reduce heart-attack-causing cholesterol in patients with familial hypercholesterolemia. Verve's proposed solution is to genetically alter the cholesterol-managing PCSK9 gene using 'VERVE-101' serum. However, a patient enrolled in the trial passed away from a heart attack last year.
The experimental biotech startup Verve Therapeutics has paused the first phase of a buzzy human gene-editing trial due to strange side effects in a patient. The trial, dubbed the 'Heart-1' trial, aims to use gene editing to reduce heart-attack-causing cholesterol in patients with familial hypercholesterolemia . Verve's proposed solution is to inject ' VERVE-101 ,' a serum designed to genetically alter the cholesterol-managing PCSK9 gene and lower fatty LDL molecules.
However, a patient enrolled in the trial passed away from a heart attack last year
Verve Therapeutics Gene-Editing Trial Side Effects Heart-1 Trial Cholesterol Familial Hypercholesterolemia LDL PCSK9 Gene VERVE-101 Heart Attack
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
HHS Secretary Becerra Emphasizes Importance of Access to COVID-19 TherapeuticsSecretary Becerra highlights the importance of access to COVID-19 therapeutics and reiterates HHS’ commitment to partnering with pharmacies and insurers to better serve the American people.
Read more »
Lenz Therapeutics' Eye Disease Drugs Meet Main Goal Of Late-stage StudyLenz Therapeutics said on Wednesday its experimental drugs to treat loss of near vision met the main goal of a late-stage study, sending its shares up nearly 23% before the...
Read more »
Lenz Therapeutics' Eye Drop Helps Improve Vision in Late-stage StudyLenz Therapeutics said on Wednesday its lead experimental drug being tested in patients with a common age-related eye disorder showed improvement in nearsightedness in a...
Read more »
Viking Therapeutics' Experimental Tablet Cuts Weight in Small StudyViking Therapeutics' experimental tablet helped reduce weight by as much as 3.3% in obese patients during a small early-stage study, meeting Wall Street expectations, and...
Read more »
Viking Therapeutics stock jumps more than 25% on promising weight loss pill dataThe Viking study results add to the growing excitement around the biotech company and its potential in the budding weight loss market.
Read more »
Viking Therapeutics' Weight-loss Tablet Shows Promise in Small StudyViking Therapeutics' experimental tablet reduced weight by as much as 3.3% when tested in volunteers enrolled in a small early-stage trial, meeting Wall Street expectations...
Read more »